APMD· Health Care› Biotechnology

Apnimed, Inc.

$18.53

-1.96% today

$771M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Not enough history to read yet

Setup score

—

Momentum

—

Edge

—

Is APMD early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2026-07-31 → 2026-10-22

S? 12w

2026-07-312026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 12w current

Total tracked: 12 weeks across 1 stage run.

APMD among Biotechnology589th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…589	APMDApnimed, Inc.	—	—	−17.6%

vs 52W High

—

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 12

1w13w26w

Week 12, early Stage 2

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

—

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.40x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-17.6%

—

YTD

—

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S—

Wk 12 · Vol 0.40x

2026-10-21S—

Wk 12 · Vol 0.53x

2026-10-20S—

Wk 12 · Vol 0.64x

2026-10-19S—

Wk 12 · Vol 0.55x

2026-10-16S—

Wk 11 · Vol 0.49x

2026-10-15S—

Wk 11 · Vol 0.53x

2026-10-14S—

Wk 11 · Vol 2.14x

2026-10-13S—

Wk 11 · Vol 0.45x

2026-10-12S—

Wk 11 · Vol 0.55x

2026-10-09S—

Wk 10 · Vol —x

2026-10-08S—

Wk 10 · Vol —x

2026-10-07S—

Wk 10 · Vol —x

Moving averages & range

50 DMA

$24.44

200 DMA

—

52W High

—

52W Low

—

5D Low

$16.60

Resistance levels (recent highs)

20d High

$23.90

60d High

—

120d High

—

250d High

—

Next resistance

+29.0%

to 20d High

P/E (TTM)

2.6

Forward -4.7

Dividend Yield

0.00%

P/B -0.5

Apnimed: quick answers

Which sector and industry is Apnimed in?

Apnimed is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.